Trypanosoma cruzi surface mucins are involved in the attachment to the Triatoma infestans rectal ampoule.


Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
05 2019
Historique:
received: 30 11 2018
accepted: 28 04 2019
revised: 31 05 2019
pubmed: 21 5 2019
medline: 28 10 2019
entrez: 21 5 2019
Statut: epublish

Résumé

Trypanosoma cruzi, the agent of Chagas disease, is a protozoan parasite transmitted to humans by blood-sucking triatomine vectors. However, and despite its utmost biological and epidemiological relevance, T. cruzi development inside the digestive tract of the insect remains a poorly understood process. Here we showed that Gp35/50 kDa mucins, the major surface glycoproteins from T. cruzi insect-dwelling forms, are involved in parasite attachment to the internal cuticle of the triatomine rectal ampoule, a critical step leading to its differentiation into mammal-infective forms. Experimental evidence supporting this conclusion could be summarized as follows: i) native and recombinant Gp35/50 kDa mucins directly interacted with hindgut tissues from Triatoma infestans, as assessed by indirect immunofluorescence assays; ii) transgenic epimastigotes over-expressing Gp35/50 kDa mucins on their surface coat exhibited improved attachment rates (~2-3 fold) to such tissues as compared to appropriate transgenic controls and/or wild-type counterparts; and iii) certain chemically synthesized compounds derived from Gp35/50 kDa mucins were able to specifically interfere with epimastigote attachment to the inner lining of T. infestans rectal ampoules in ex vivo binding assays, most likely by competing with or directly blocking insect receptor(s). A solvent-exposed peptide (smugS peptide) from the Gp35/50 kDa mucins protein scaffolds and a branched, Galf-containing trisaccharide (Galfβ1-4[Galpβ1-6]GlcNAcα) from their O-linked glycans were identified as main adhesion determinants for these molecules. Interestingly, exogenous addition of a synthetic Galfβ1-4[Galpβ1-6]GlcNAcα derivative or of oligosaccharides containing this structure impaired the attachment of Dm28c but not of CL Brener epimastigotes to triatomine hindgut tissues; which correlates with the presence of Galf residues on the Gp35/50 kDa mucins' O-glycans on the former but not the latter parasite clone. These results provide novel insights into the mechanisms underlying T. cruzi-triatomine interplay, and indicate that inter-strain variations in the O-glycosylation of Gp35/50 kDa mucins may lead to differences in parasite differentiation and hence, in parasite transmissibility to the mammalian host. Most importantly, our findings point to Gp35/50 kDa mucins and/or the Galf biosynthetic pathway, which is absent in mammals and insects, as appealing targets for the development of T. cruzi transmission-blocking strategies.

Sections du résumé

BACKGROUND
Trypanosoma cruzi, the agent of Chagas disease, is a protozoan parasite transmitted to humans by blood-sucking triatomine vectors. However, and despite its utmost biological and epidemiological relevance, T. cruzi development inside the digestive tract of the insect remains a poorly understood process.
METHODS/PRINCIPLE FINDINGS
Here we showed that Gp35/50 kDa mucins, the major surface glycoproteins from T. cruzi insect-dwelling forms, are involved in parasite attachment to the internal cuticle of the triatomine rectal ampoule, a critical step leading to its differentiation into mammal-infective forms. Experimental evidence supporting this conclusion could be summarized as follows: i) native and recombinant Gp35/50 kDa mucins directly interacted with hindgut tissues from Triatoma infestans, as assessed by indirect immunofluorescence assays; ii) transgenic epimastigotes over-expressing Gp35/50 kDa mucins on their surface coat exhibited improved attachment rates (~2-3 fold) to such tissues as compared to appropriate transgenic controls and/or wild-type counterparts; and iii) certain chemically synthesized compounds derived from Gp35/50 kDa mucins were able to specifically interfere with epimastigote attachment to the inner lining of T. infestans rectal ampoules in ex vivo binding assays, most likely by competing with or directly blocking insect receptor(s). A solvent-exposed peptide (smugS peptide) from the Gp35/50 kDa mucins protein scaffolds and a branched, Galf-containing trisaccharide (Galfβ1-4[Galpβ1-6]GlcNAcα) from their O-linked glycans were identified as main adhesion determinants for these molecules. Interestingly, exogenous addition of a synthetic Galfβ1-4[Galpβ1-6]GlcNAcα derivative or of oligosaccharides containing this structure impaired the attachment of Dm28c but not of CL Brener epimastigotes to triatomine hindgut tissues; which correlates with the presence of Galf residues on the Gp35/50 kDa mucins' O-glycans on the former but not the latter parasite clone.
CONCLUSION/SIGNIFICANCE
These results provide novel insights into the mechanisms underlying T. cruzi-triatomine interplay, and indicate that inter-strain variations in the O-glycosylation of Gp35/50 kDa mucins may lead to differences in parasite differentiation and hence, in parasite transmissibility to the mammalian host. Most importantly, our findings point to Gp35/50 kDa mucins and/or the Galf biosynthetic pathway, which is absent in mammals and insects, as appealing targets for the development of T. cruzi transmission-blocking strategies.

Identifiants

pubmed: 31107901
doi: 10.1371/journal.pntd.0007418
pii: PNTD-D-18-01888
pmc: PMC6544316
doi:

Substances chimiques

Mucins 0
Protozoan Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0007418

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist

Références

Parasitol Res. 1998 Jul;84(7):527-36
pubmed: 9694367
PLoS Pathog. 2016 Apr 08;12(4):e1005559
pubmed: 27058585
PLoS Negl Trop Dis. 2014 Jun 05;8(6):e2906
pubmed: 24901991
PLoS Negl Trop Dis. 2017 Aug 11;11(8):e0005856
pubmed: 28800609
J Proteome Res. 2013 Feb 1;12(2):883-97
pubmed: 23214914
J Biol Chem. 2005 Apr 1;280(13):12201-11
pubmed: 15649890
Exp Parasitol. 2018 Dec;195:24-33
pubmed: 30261188
Parasit Vectors. 2016 Dec 9;9(1):636
pubmed: 27938415
Carbohydr Res. 1997 Dec;305(2):163-70
pubmed: 9581272
PLoS Negl Trop Dis. 2012;6(12):e1958
pubmed: 23272264
Nat Rev Microbiol. 2006 Mar;4(3):229-36
pubmed: 16489349
Parasite Immunol. 1993 Feb;15(2):121-5
pubmed: 8446464
Mol Biochem Parasitol. 1985 Sep;16(3):315-27
pubmed: 3903496
Subcell Biochem. 2014;74:253-70
pubmed: 24264249
Org Lett. 1999 Jul 29;1(2):245-7
pubmed: 10905870
Microbes Infect. 2006 Feb;8(2):401-9
pubmed: 16253534
Mol Biochem Parasitol. 2004 Jan;133(1):81-91
pubmed: 14668015
Science. 2005 Jul 15;309(5733):409-15
pubmed: 16020725
Exp Parasitol. 1996 Jun;83(1):83-93
pubmed: 8654555
Trends Parasitol. 2013 Apr;29(4):188-96
pubmed: 23507033
Biochem J. 2012 Jun 1;444(2):211-8
pubmed: 22428617
J Invertebr Pathol. 2013 Mar;112 Suppl:S75-82
pubmed: 22841635
Eukaryot Cell. 2005 Jun;4(6):1147-54
pubmed: 15947206
Mol Biochem Parasitol. 2001 May;114(2):143-50
pubmed: 11378194
J Org Chem. 1996 Mar 8;61(5):1886-1889
pubmed: 11667072
Methods Mol Biol. 2019;1955:119-134
pubmed: 30868523
Infect Immun. 1992 Nov;60(11):4673-8
pubmed: 1328061
J Biol Chem. 2013 Mar 22;288(12):8772-84
pubmed: 23386612
PLoS Negl Trop Dis. 2018 Jul 23;12(7):e0006661
pubmed: 30036366
Org Biomol Chem. 2012 Aug 21;10(31):6322-32
pubmed: 22735493
Mem Inst Oswaldo Cruz. 1997 Jan-Feb;92(1):91-6
pubmed: 9302418
Parasitol Today. 2000 Sep;16(9):381-7
pubmed: 10951597
Infect Immun. 2005 Dec;73(12):7797-807
pubmed: 16299269
J Biol Chem. 1995 Nov 10;270(45):27244-53
pubmed: 7592983
Science. 1981 Feb 6;211(4482):597-600
pubmed: 7006082
Trends Parasitol. 2017 Feb;33(2):102-112
pubmed: 27843019
Adv Parasitol. 2017;97:1-45
pubmed: 28325368
Biochem J. 2011 Sep 1;438(2):303-13
pubmed: 21651499
Exp Parasitol. 1987 Oct;64(2):252-60
pubmed: 2820783
Parasit Vectors. 2016 Jul 25;9(1):413
pubmed: 27457627
Parasit Vectors. 2018 Feb 6;11(1):83
pubmed: 29409544
Exp Parasitol. 2007 Jun;116(2):120-8
pubmed: 17306256
Proteomics. 2012 Aug;12(17):2694-703
pubmed: 22761176
PLoS Negl Trop Dis. 2015 Feb 12;9(2):e0003358
pubmed: 25675102
Exp Parasitol. 2003 Mar-Apr;103(3-4):102-11
pubmed: 12880586
Enzyme Res. 2011;2011:415976
pubmed: 21687654
Parasitology. 2015 Jul;142(8):1024-32
pubmed: 25823521
Curr Pharm Des. 2001 Aug;7(12):1165-79
pubmed: 11472260
Parasit Vectors. 2014 May 20;7:232
pubmed: 24885969
Curr Opin Struct Biol. 2002 Oct;12(5):616-23
pubmed: 12464313
J Biol Chem. 2000 Apr 7;275(14):10218-27
pubmed: 10744707
Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):14936-41
pubmed: 26627243
Parasit Vectors. 2013 Mar 14;6:65
pubmed: 23497594
Adv Carbohydr Chem Biochem. 2009;62:311-66
pubmed: 19501708
Eur J Biochem. 1989 Jun 15;182(2):413-21
pubmed: 2472273
J Cell Biol. 1988 Apr;106(4):1349-58
pubmed: 3283152
Carbohydr Res. 2010 Feb 11;345(3):385-96
pubmed: 20044082
J Biol Chem. 1991 Dec 15;266(35):23670-5
pubmed: 1748644
Exp Parasitol. 1998 Sep;90(1):20-5
pubmed: 9709026
Exp Parasitol. 1996 Mar;82(2):112-21
pubmed: 8617337
J Biol Chem. 2012 Jul 27;287(31):26365-76
pubmed: 22707724
PLoS Negl Trop Dis. 2019 Mar 14;13(3):e0007245
pubmed: 30870417
J Parasitol. 2000 Dec;86(6):1213-8
pubmed: 11191893
Biochemistry. 2004 Sep 21;43(37):11889-97
pubmed: 15362875
Vaccine. 2016 Jun 3;34(26):2996-3000
pubmed: 27026146
PLoS One. 2012;7(5):e36591
pubmed: 22574189
Acta Trop. 1997 Nov;68(2):159-73
pubmed: 9386791
J Proteomics. 2017 Jan 16;151:182-192
pubmed: 27318177
Mol Biochem Parasitol. 1993 Jun;59(2):293-303
pubmed: 8341326
J Cell Sci. 2015 Jul 1;128(13):2213-9
pubmed: 26092931
Infect Genet Evol. 2012 Mar;12(2):240-53
pubmed: 22226704
Parasit Vectors. 2011 Mar 18;4:39
pubmed: 21418565
PLoS Negl Trop Dis. 2013 Nov 14;7(11):e2552
pubmed: 24244781
Carbohydr Res. 2006 Jul 24;341(10):1488-97
pubmed: 16630598
Glycoconj J. 2010 Jul;27(5):549-59
pubmed: 20645127
Mol Biochem Parasitol. 1997 Jan;84(1):57-67
pubmed: 9041521
Infect Immun. 1989 Jun;57(6):1663-7
pubmed: 2656520
J Exp Med. 2002 Feb 18;195(4):401-13
pubmed: 11854354
Glycoconj J. 2013 Oct;30(7):659-66
pubmed: 23430107
Microbiol Mol Biol Rev. 2007 Jun;71(2):282-94
pubmed: 17554046
Glycobiology. 2012 Apr;22(4):456-69
pubmed: 21940757
Mol Syst Biol. 2009;5:261
pubmed: 19357640

Auteurs

María de Los Milagros Cámara (MLM)

Instituto de Investigaciones Biotecnológicas-Instituto Tecnológico de Chascomús (IIB-INTECh), Universidad Nacional de San Martín (UNSAM) and Consejo Nacional de investigaciones científicas y técnicas (CONICET), Buenos Aires, Argentina.

Virginia Balouz (V)

Instituto de Investigaciones Biotecnológicas-Instituto Tecnológico de Chascomús (IIB-INTECh), Universidad Nacional de San Martín (UNSAM) and Consejo Nacional de investigaciones científicas y técnicas (CONICET), Buenos Aires, Argentina.

Camila Centeno Cameán (C)

Instituto de Investigaciones Biotecnológicas-Instituto Tecnológico de Chascomús (IIB-INTECh), Universidad Nacional de San Martín (UNSAM) and Consejo Nacional de investigaciones científicas y técnicas (CONICET), Buenos Aires, Argentina.

Carmen R Cori (CR)

Universidad de Buenos Aires, Facultad de Ciencias Exactas y Naturales, Departamento de Química Orgánica, Pabellón 2, Ciudad Universitaria, C1428EGA Buenos Aires, Argentina.
CONICET-UBA, Centro de Investigación en Hidratos de Carbono (CIHIDECAR), C1428EGA Buenos Aires, Argentina.

Gustavo A Kashiwagi (GA)

Universidad de Buenos Aires, Facultad de Ciencias Exactas y Naturales, Departamento de Química Orgánica, Pabellón 2, Ciudad Universitaria, C1428EGA Buenos Aires, Argentina.
CONICET-UBA, Centro de Investigación en Hidratos de Carbono (CIHIDECAR), C1428EGA Buenos Aires, Argentina.

Santiago A Gil (SA)

Universidad de Buenos Aires, Facultad de Ciencias Exactas y Naturales, Departamento de Química Orgánica, Pabellón 2, Ciudad Universitaria, C1428EGA Buenos Aires, Argentina.
CONICET-UBA, Centro de Investigación en Hidratos de Carbono (CIHIDECAR), C1428EGA Buenos Aires, Argentina.

Natalia Paula Macchiaverna (NP)

Laboratorio de Eco-Epidemiología, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires e Instituto de Ecología, Genética y Evolución de Buenos Aires (IEGEBA), UBA-CONICET, C1428EGA Buenos Aires, Argentina.

Marta Victoria Cardinal (MV)

Laboratorio de Eco-Epidemiología, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires e Instituto de Ecología, Genética y Evolución de Buenos Aires (IEGEBA), UBA-CONICET, C1428EGA Buenos Aires, Argentina.

Francisco Guaimas (F)

Instituto de Investigaciones Biotecnológicas-Instituto Tecnológico de Chascomús (IIB-INTECh), Universidad Nacional de San Martín (UNSAM) and Consejo Nacional de investigaciones científicas y técnicas (CONICET), Buenos Aires, Argentina.

Maite Mabel Lobo (MM)

Instituto de Investigaciones Biotecnológicas-Instituto Tecnológico de Chascomús (IIB-INTECh), Universidad Nacional de San Martín (UNSAM) and Consejo Nacional de investigaciones científicas y técnicas (CONICET), Buenos Aires, Argentina.

Rosa M de Lederkremer (RM)

Universidad de Buenos Aires, Facultad de Ciencias Exactas y Naturales, Departamento de Química Orgánica, Pabellón 2, Ciudad Universitaria, C1428EGA Buenos Aires, Argentina.
CONICET-UBA, Centro de Investigación en Hidratos de Carbono (CIHIDECAR), C1428EGA Buenos Aires, Argentina.

Carola Gallo-Rodriguez (C)

Universidad de Buenos Aires, Facultad de Ciencias Exactas y Naturales, Departamento de Química Orgánica, Pabellón 2, Ciudad Universitaria, C1428EGA Buenos Aires, Argentina.
CONICET-UBA, Centro de Investigación en Hidratos de Carbono (CIHIDECAR), C1428EGA Buenos Aires, Argentina.

Carlos A Buscaglia (CA)

Instituto de Investigaciones Biotecnológicas-Instituto Tecnológico de Chascomús (IIB-INTECh), Universidad Nacional de San Martín (UNSAM) and Consejo Nacional de investigaciones científicas y técnicas (CONICET), Buenos Aires, Argentina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH